Evidence map›Paper›PMID 38012220›Full record

ArticleScientific reports2023

A human bispecific antibody neutralizes botulinum neurotoxin serotype A.

Jiansheng Lu, Yujia Jiang, Jiazheng Guo, Lei Chen, Fujia Liu, Zhiying Li, Xuyang Liu, Peng Du, Yunzhou Yu, Rong Wang and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Dual-Toxin-ProducingToxins · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jiansheng Lu *Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Yujia Jiang *Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Jiazheng GuoLaboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Lei ChenLaboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Fujia LiuLaboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Zhiying LiLaboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Xuyang LiuLaboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Peng DuLaboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
Yunzhou YuLaboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China. yunzhouyu@163.com.
Rong WangLaboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China. wangrong_8312@163.com.
Zhixin YangLaboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China. yy_xiao@126.com.
Beijing Proteome Research Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Botulinum neurotoxin (BoNT) shows high lethality and toxicity, marking it as an important biological threat. The only effective post-exposure therapy is botulinum antitoxin; however, such products have great potential for improvement. To prevent or treat BoNT, monoclonal antibodies (mAbs) are promising agents. Herein, we aimed to construct a bispecific antibody (termed LUZ-A1-A3) based on the anti-BoNT/A human monoclonal antibodies (HMAb) A1 and A3. LUZ-A1-A3 binds to the Hc and L-HN domains of BoNT/A, displaying potent neutralization activity against BoNT/A (124 × higher than that of HMAb A1 or HMAb A3 alone and 15 × higher than that of the A1 + A3 combination). LUZ-A1-A3 provided effective protection against BoNT/A in an in vivo mouse model. Mice were protected from infection with 500 × LD

Indexed as

Botulinum Toxins, Type ABotulismAnimalsAntibodies, MonoclonalDisease Models, AnimalHumansLethal Dose 50MiceSerogroupAntibodies, MonoclonalBotulinum Toxins, Type A

Identifiers

PMID38012220
PMCPMC10681988
OpenAlexW4389039023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.